Healthcare marketing enforcement in 2024 and early 2025 set a trajectory that is shaping what to expect across 2026. Specific categories are receiving more attention, specific patterns are drawing more letters, and specific enforcement mechanisms are becoming more prominent. This post is a forward-looking analysis of where enforcement is heading and what practices should adjust now to stay ahead.
Trend 1: Compounded medication scrutiny deepens
The compounded GLP-1 enforcement wave that began in 2024 shows no signs of slowing. Expect:
- Continued FDA warning letters on compounded GLP-1 equivalency language.
- Expansion of enforcement interest to other compounded drug categories - compounded hormones, compounded peptides, compounded cosmetic preparations.
- State AG coordination with federal enforcement on compounded medication marketing.
- Private class action activity on compounded-equivalency marketing deception.
What to do: audit all compounded-drug marketing for equivalency language and correct. This applies beyond GLP-1 - the pattern is category-wide.
Trend 2: Aesthetic device enforcement intensifies
FDA-cleared vs FDA-approved misuse in aesthetic device marketing has been increasing as an enforcement pattern. Expect:
- More specific FDA letters on device-category marketing - lasers, RF, body contouring.
- Off-label body-area marketing increasingly cited.
- Before/after transformation marketing facing both FTC and platform-policy pressure simultaneously.
- Supervision-language enforcement coordinated between state medical boards and FDA.
Trend 3: AI-generated content and fake testimonials
The 2023 FTC Endorsement Guides update specifically addressed AI-generated testimonials and stock-image before/afters as deceptive. Expect active enforcement in 2026:
- FTC actions against practices using AI-generated patient testimonials.
- Increased scrutiny of stock-imagery used as “patient” content.
- AI-generated copy making confident health claims that fail substantiation review.
- Platform policy enforcement on AI-generated content disclosure.
What to do: verify every testimonial is real; verify every patient image is a real patient with proper authorization; review any AI-generated marketing copy for substantiation issues before publishing.
Trend 4: Longevity and anti-aging claims
NAD+, peptides, hormone therapy, and related longevity- focused services face growing FTC attention. Expect:
- Continued FTC action against specific NAD+ marketers.
- Expansion to peptide-based longevity claims.
- Anti-aging claims in hormone therapy marketing under increased scrutiny.
- “Longevity medicine” framing specifically reviewed when paired with outcome claims.
Trend 5: Telehealth advertising rules firm up
Telehealth-specific advertising rules have grown across states. Expect:
- More state-level telehealth advertising enforcement.
- Continued DEA and FDA attention on controlled-substance telehealth marketing (ketamine, hormones).
- State AG actions on cross-border telehealth advertising.
- Licensure-disclosure requirements tightening.
Trend 6: Platform policy tightening
Meta, Google, and TikTok have been tightening healthcare advertising policies. Expect:
- More ad disapproval and account restriction.
- Weight-loss advertising policy continuing to tighten.
- Before/after imagery restrictions expanding.
- Certification requirements expanding to additional specialties.
Trend 7: State AG coordination and private action
State AG activity and private class action exposure are both growing. Expect:
- More multi-state coordinated investigations.
- Private class actions mirroring AG action on similar patterns.
- State-level parallel action to federal FDA and FTC cases.
Trend 8: Social media enforcement volume
Social media marketing is increasingly the surface where enforcement begins. Expect:
- Continued FTC attention to TikTok healthcare content.
- More Instagram-specific enforcement of Endorsement Guides violations.
- YouTube health content drawing specific FTC attention.
- Enforcement scaling as agencies develop better tooling for social media review.
Trend 9: Corporate practice of medicine
Non-physician-owned healthcare entities - franchise med spas, telehealth platforms, corporate-owned practices - face increasing scrutiny in states with strict corporate practice rules. Expect:
- More state AG attention to corporate-practice structures.
- Marketing that implies non-physician entities provide medical services specifically flagged.
- State medical board coordination with AG enforcement.
Trend 10: Documentation expectations rise
Regulators increasingly expect documented compliance programs as part of healthcare operations. Expect:
- Warning letter responses asking for compliance-program documentation.
- State medical board discipline considering compliance program evidence.
- Court considerations in private action giving weight to documented compliance.
- Insurance coverage considerations factoring in compliance documentation.
What to prepare for
Documented compliance program
If you don’t have one, build it. Written style guide, pre-publish review process, trained staff, audit schedule, incident response plan.
Current inventory of marketing surfaces
Know what’s out there. Website, social accounts, ad creative, email campaigns, staff bios, patient-facing communications. A current inventory is the first step in any compliance program.
Regular audit cadence
Quarterly audits of current marketing against current rules. Enforcement priorities shift; static audits from a year ago miss new patterns.
Legal counsel relationship
If you don’t already have healthcare regulatory counsel, establish the relationship before you need it. Finding counsel the day a warning letter arrives is both slower and more expensive.
Multi-state awareness
If you market across states, know the multi-state exposure. State AG activity is one of the fastest-moving enforcement vectors.
Platform policy monitoring
For practices doing significant paid advertising, subscribe to platform policy updates. Policy changes with 30-day notice affect your active campaigns.
The enforcement environment in 2026 rewards practices that invested in compliance programs before they had to - and penalizes practices that treated compliance as overhead rather than infrastructure. The gap between these two postures is wider than it’s ever been, and growing.
Frequently asked questions
Are there categories likely to receive less enforcement attention?
Established service categories with strong manufacturer support and mature compliance norms (e.g., FDA-approved filler marketing that follows manufacturer guidance) face less enforcement scrutiny than emerging or loosely-regulated categories. But category-wide enforcement lulls don’t protect individual practices with specific claim issues.
Should small practices worry about enforcement?
Yes. The Wellbeing Corporation case demonstrated that FTC enforcement reaches small operations. FDA warning letters regularly go to single-location clinics. State AGs pursue local practices. Size is not protection.
How quickly do enforcement trends develop?
Specific patterns develop over 12-36 months from initial letters to category-defining cases. Agencies telegraph priorities in guidance documents, public statements, and coordinated announcements. Staying current on these communications gives you lead time.
What about the next administration’s enforcement priorities?
Administration changes affect enforcement priorities to some degree, but healthcare marketing enforcement has been relatively consistent across administrations because the underlying statutes (FD&C Act, FTC Act) don’t change. Specific emphases may shift; the general framework is stable.
Is compliance software becoming more important?
The volume of marketing to review, the rate of enforcement trend changes, and the specificity required in compliance analysis all push toward tooling. Manual review at scale is increasingly impractical. Most established healthcare marketers are adopting compliance software in some form.
What’s the single-best compliance investment for 2026?
Pre-publish compliance review as a systematic step in the publishing workflow, backed by a documented written style guide and regular staff training. This closes the gap between “we know the rules” and “the rules are applied consistently.”